Table 2.
SVR12 according to patient baseline characteristics (ITT population)
| n/N (%) | Phase 2/3 group (N = 125) | Phase 1 group (N = 16)a |
|---|---|---|
| HCV geno/subtype | ||
| 1a | 33/50 (66.0) | 5/14 (35.7) |
| with baseline Q80K | 8/12 (66.7) | 2/3 (66.7) |
| without baseline Q80K | 25/38 (65.8) | 3/11 (27.3) |
| 1b | 54/75 (72.0) | 1/2 (50.0) |
| IL28B | ||
| CC | 17/20 (85.0) | 1/1 (100.0) |
| CT | 58/87 (66.7) | 3/9 (33.3) |
| TT | 12/18 (66.7) | 2/6 (33.3) |
| HOMA-IR | ||
| <2 | 39/46 (84.8) | 2/4 (50.0) |
| ≥2 to ≤4 | 25/43 (58.1) | 3/7 (42.9) |
| >4 | 20/31 (64.5) | 0/3 |
| METAVIR fibrosis score | ||
| F0–F2 | 64/85 (75.3) | 5/13 (38.5) |
| F3–F4 | 23/40 (57.5) | 1/3 (33.3) |
| F3 | 11/18 (61.1) | 1/3 (33.3) |
| F4 | 12/22 (54.5) | 0 |
aDue to small patient numbers, these data should be interpreted with caution
HCV hepatitis C virus, HOMA-IR homeostatic model assessment of insulin resistance, IL28B interleukin-28b, ITT intent-to-treat, SVR12 sustained virologic response 12 weeks after planned end of treatment